News from our community

FOR IMMEDIATE RELEASE

TriAltus Bioscience Extends Patent Protection for CLīM Protein Purification Technology

BIRMINGHAM, Ala., August 20, 2024 -- TriAltus Bioscience announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12030913 for its innovative CL7/Im7, branded as “CLīM”, technology.

The patented "Bacterial Colicin-Immunity Protein Purification System" features an engineered Colicin Immunity protein (Im7) designed to enhance binding and stability. Im7 is integral to the CLīM protein purification system, where it can be immobilized on solid supports or substrates for diverse applications. CLīM utilizes the high affinity between the engineered CL7 affinity tag and Im7 ligand to achieve highyield, high-purity protein purification, addressing limitations seen in other affinity systems.

The technology has been licensed from the University of Alabama at Birmingham, where Dmitry Vassylyev, Ph.D., professor of biochemistry and molecular genetics, led the invention efforts.

CEO Bob Shufflebarger commented, “This patent reinforces the foundational technology that enables TriAltus to produce and market engineered enzymes of exceptional quality and value. We anticipate that enhancing the value proposition for end-users will drive market expansion, influencing procurement decisions within the life science and biotech sectors, thereby allowing them to focus on discovery and development.”

“The new patent is the second U.S. patent issued for Dr. Vassylyev’s innovative protein purification technology,” said Kathy Nugent, Ph.D., Executive Director of UAB’s Harbert Institute for Innovation and Entrepreneurship. "Protein purification is vital to biotechnological processes, and this method is inexpensive yet efficient. We are proud that this UAB-developed technology may, in turn, drive new innovation in biotechnology."

About TriAltus Bioscience

TriAltus Bioscience harnesses its proprietary CLīM affinity purification system to deliver proteins with exceptional purity and yield, streamlining the production process. TriAltus has demonstrated the effectiveness of its technology on a variety of complex proteins and is now forming strategic partnerships to apply its systems to bespoke customer projects.

For more information, visit Protein Purification Simplified – TriAltus Bioscience

Contact:

Tessa Blackburn

Director, Business Development TriAltus Bioscience

tessa.blackburn@trialtusbioscience.com

+1 (205) 453-8242

Evonik honored with Trade Excellence Award in Alabama Award recognizes positive impact of global trade on regional economy Evonik part of the Birmingham Biotechnology Hub Mobile/Birmingham, AL, May 09, 2024 - Evonik, one of the world’s leading specialty chemicals companies, was honored by Alabama Governor Kay Ivey with the 2024 Governor’s Trade Excellence Award during a special ceremony at the State Capitol in Montgomery, Ala.   The award recognizes excellence in exporting by companies in Alabama and aims to raise awareness of the positive impact of global trade on the state’s economy.   Evonik employs approximately 1,000 people in Alabama at its sites in Mobile and Birmingham.   “The award is a great honor for Evonik, and we are grateful to local, state, and federal partners for their support of our growth and export strategy,” said Kel Boisvert, member of Evonik’s North America Leadership Team (NALT) and site manager in Mobile.   Evonik manufactures specialty chemicals for a variety of products at the Mobile site, including coating additives for wind turbine blades, structural foams for aircraft, catalysts for biodiesel production, and amino acids for optimized livestock farming.   In Birmingham, Evonik specializes in bioabsorbable polymers and drug delivery techniques for pharmaceutical, biotechnology, and medical device companies. Evonik is part of the Birmingham Biotechnology Hub, a regional consortium of public, private, and academic partners which recently received a Federal Tech Hub designation. The Tech Hubs Program was enacted as part of the CHIPS and Science Act of 2022 and aims to catalyze growth in critical industries.   “Evonik is pleased to contribute to the booming bioscience industry in Birmingham,” remarked Hans Thullesen, site manager of Evonik Birmingham Labs. “Receiving the Governor’s Trade Excellence Award underscores the importance of biotechnology not just in Alabama, but across the globe.”   Alabama-based companies exported goods and services worth over $27.4 billion in 2023, according to the Alabama Department of Commerce. Germany was the top destination with $5.1 billion.   Link to press release and images   For additional information about Evonik in North America, please visit our website: http://corporate.evonik.us/region/north_america.

 FOR IMMEDIATE RELEASE

Acclinate Empowers Black Maternal Health with AI-Powered Cultural Understanding

Birmingham, AL – April 24, 2024 – Acclinate, a pioneer in health equity through technology and community engagement, has partnered with Quilt.AI, a company at the forefront of employing artificial intelligence (AI) to understand and interpret internet data at scale to intensify its Black maternal health initiatives. With Black women in the United States facing a maternal mortality rate three times higher than that of white women, Acclinate's efforts are more crucial than ever.

Over the past year, Acclinate’s NOWINCLUDED community platform has engaged directly with Black mothers, gathering invaluable insights through the Mommy Listening Tour, a campaign focused on better understanding the health perspectives of Black moms. The tour, which utilized digital and in-person efforts, revealed that 75% of Black mothers trust OBGYNs for reliable health information, and over 51% are willing to travel up to 10 miles for quality maternal care. These findings stress the need for accessible and culturally responsive healthcare solutions.

The NOWINCLUDED team also recently had the opportunity to hear directly from Black mothers at the Black Maternal Health Expo at Babypalooza, further enriching the company's understanding of their experiences and needs. This face-to-face engagement has been instrumental in shaping our ongoing initiatives.

To amplify these efforts, Acclinate is leveraging additional findings from Quilt.AI's advanced AI platform, which has been dissecting online conversations about Black maternal health, producing a comprehensive report. The report confirms that a significant 75% of online discussions highlight a pressing need for better support systems for Black mothers, while another 63% underscore a demand for more culturally competent healthcare providers. Additional insights indicate a substantial conversation around the need for mental health support, with many Black mothers expressing a lack of accessible resources to manage postpartum depression.

Tiffany Whitlow, Co-Founder and Chief Development Officer at Acclinate, remarks, "Leveraging these insights allows us to tailor our initiatives more effectively, ensuring we address the nuanced challenges Black mothers face in healthcare. Our Mommy Listening Tour and most recent listening experiences at the Black Maternal Health Expo have been invaluable, offering direct feedback from our community so we can work together to advocate for better maternal health outcomes. "

Anurag Banerjee, co-founder and chief executive officer of Quilt.AI adds, "We're extremely excited to partner with Acclinate and contribute our AI tools to uncover meaningful health insight to support Acclinate's mission and help drive positive impact and better serve Black women in the community."

As Acclinate continues its efforts, the organization is poised to introduce innovative solutions and solidify its commitment to improving maternal health outcomes for Black women, ensuring that their voices are heard and their health is prioritized.

About Acclinate:

Acclinate, a digital health startup dedicated to improving health equity, specializes in predictive analytics technology and community engagement. Focused on accessing and engaging communities of color, Acclinate empowers informed health decisions and promotes clinical trial participation. Learn more at acclinate.com.

About Quilt.AI:

Quilt.AI is a technology company that aims to bridge the gap between data and culture, using AI to uncover human insights from vast amounts of digital information. With a commitment to ethical data usage, Quilt.AI serves a diverse range of clients, from Fortune 100 companies to nonprofits, helping them understand the cultural contexts behind data. Quilt.AI has been called a “AI for Good” company by the Economist. Learn more at www.quilt.ai.

For media inquiries or additional information, please contact:

Romario Gardner

Public Relations Specialist

Romario@acclinate.com

256-435-2800

CerFlux Awarded $100,000 Innovate Alabama Grant to Advance Cancer Research from Lab-to-Life

BIRMINGHAM, Ala., (Apr 11, 2024) – CerFlux, Inc., creators of advanced personalized medicine technology for cancer treatment, announced today that it has been awarded a $100,000 Innovate Alabama grant. This competitive grant award will support the development of our innovative ChipMux® technology, aimed at revolutionizing the approach to cancer treatment.

Every year, about 2 million Americans are diagnosed with cancer. Worse, treatment turns out to be ineffective for about 75% of solid tumor patients who receive systemic therapy. This is because every tumor is distinct in makeup and response to treatment. Unfortunately, a generalized treatment approach is forced upon a disease that is uniquely personal due to lack of personalized predictive tools. Consequently, patients are exposed to several rounds of potentially harmful overtreatment until the right regimen is found, imposing a substantial physical, emotional, and financial burden. Adding insult to injury, over 40% of patients deplete their entire life savings in just 2 years.

CerFlux ChipMux technology addresses this critical, urgent, and unmet need for accessible and affordable predictive technologies that identify optimal therapy regimens and strategically eliminate ineffective options. This project represents a major departure from the generalized one-size-fits-none approach to cancer treatment. If successful, our patented biopsy chip multiplexer technology will screen multiple anticancer regimens simultaneously on intact core biopsy tissue from each patient’s own tumor – before treatment – to identify the right treatment for that patient. The ultimate aim of this groundbreaking technology is to eliminate ineffective treatment regimens and identify the most effective regimens for each patient on an individualized basis.

“During this SBIR Phase I project, we will address several key objectives from bioprinting 3D tumor proxies to demonstrating the predictive capacity of this platform for personalized cancer treatment,” explains Dr. Karim Budhwani, CEO of CerFlux, Inc. “If successful, this personalized approach will not only reduce the cost of cancer treatment but, more importantly, it will substantially lighten the emotional, physical, and financial burden suffered by patients.”

In an era where precision and personalization are becoming increasingly vital in medicine, ChipMux technology holds the promise to set a new standard in cancer treatment: The right treatment at the right time for each patient on an individualized basis. Predictive technologies like ChipMux – that match each patient with the right treatment regimen BEFORE treatment is administered – will make a profound impact on the lives of cancer patients, offer substantial cost savings to insurance providers, and strengthen US leadership in advanced research.

​The Innovate Alabama Supplemental Grant Program provides non-dilutive funding to companies that have previously received federal SBIR or STTR grants. The grants are designed to support the growth and success of Alabama-based companies, as well as recruit new businesses to the state. The receipt of this grant highlights the potential impact of ChipMux on improving cancer treatment and patient outcomes. The grant will fund activities over the next year to help bring us a step closer in making personalized precision cancer treatment a reality for patients around the world.

About CerFlux, Inc.

CerFlux, Inc. is a Birmingham (Alabama) based cancer biotech company. CerFlux is creating advanced, personalized medicine solutions, including its patented ChipMux® biopsy-on-a-chip for simultaneously testing multiple anticancer agents directly on standard-of-care tumor biopsy tissue. Our goal is to apply this biopsy-on-a-chip technology across the cancer care continuum; from improving AI in cancer drug response prediction with PROPHET, predicting clinical efficacy for preclinical compounds with PEER® to improving clinical trials with POETRY and identifying the most effective cancer treatments for each patient on an individualized basis with POET®. By building solutions that quickly and clearly separate optimal from ineffective options, we will improve treatment outcomes and quality of life for cancer patients.

About Innovate Alabama

Innovate Alabama is Alabama’s first statewide public-private partnership focused on entrepreneurship, technology and innovation with a mission to help innovators grow roots here in Alabama. Innovate Alabama was established to implement the initiatives and recommendations set forth in the Alabama Innovation Commission’s report, including smart policy solutions that will create a more resilient, inclusive and robust economy to remain competitive in a 21st-century world. With founding CEO Cynthia Crutchfield leading the charge, Innovate Alabama is also made up of a board of 11 innovation leaders appointed by Gov. Ivey, collaborating across sectors to advance industries, drive technology and facilitate an environment where innovation and entrepreneurship thrive. Learn more about Innovate Alabama at www.innovatealabama.org.

Additional Information

To request collateral materials for publication or to schedule interviews with principals from CerFlux, Inc., please contact Rachel Stacey at rss@CerFlux.com for availability.

 Acclinate Celebrates Victory in the 3rd Annual Anthem Awards

Birmingham, AL, January 30, 2024 – Acclinate, a trailblazer in advancing health equity through inclusive research, proudly announces its achievement as a Winner in the esteemed Diversity, Equity, & Inclusion category of the 3rd Annual Anthem Awards.

The Anthem Awards, hosted by the International Academy of Digital Arts and Sciences, is a prestigious event bringing together influential figures to honor outstanding achievements in purpose-driven initiatives globally.

Acclinate's innovative approach, blending predictive analytics technology with empowered community building, has not only supported pharmaceutical companies in actively increasing representation in clinical trials but has also championed inclusivity in broader healthcare initiatives. Serving as a catalyst, Acclinate transforms trust and data into products that better serve communities of color.

Tiffany Whitlow, Chief Development Officer, and co-founder of Acclinate, expressed her excitement, saying, "From the beginning, we recognized the need to change the perception of healthcare, particularly concerning the care of minority communities. Through various mediums, including video storytelling, we have consistently engaged our audience by shedding light on health narratives often overlooked. This accolade underscores our commitment to fostering diversity and health equity in clinical trials, and we are deeply honored by this recognition of our efforts."

For more information on Acclinate, please visit www.acclinate.com and connect with us on LinkedIn. To learn more about NOWINCLUDED and join the community built for healthier communities of color, visit www.NOWINCLUDED.com and follow us on Instagram.

Acclinate Media Contact:

Ellie Newby, Head of Marketing & Communications

ellie@acclinate.com                                                                256-435-2800

Find The Anthem Awards Online:

● Website: anthemawards.com

● Facebook: facebook.com/anthemawards

● Twitter: @anthemawards

● Instagram: @anthemawards

● LinkedIn: The Anthem Awards

● YouTube: wbby.co/anthem-youtube

About The Anthem Awards:

Launched in 2021 by The Webby Awards, The Anthem Awards honor purpose-driven work globally across seven core causes, including Diversity; Equity & Inclusion; Education; Art & Culture; Health; Human & Civil Rights; Humanitarian Action & Services; Responsible Technology; and Sustainability, Environment & Climate. Founded in partnership with influential organizations such as the Ad Council, Born This Way Foundation, Feeding America, Glaad, Mozilla, NAACP, NRDC, WWF, and XQ.

Empowering Healthcare Equity: Celebrating 4 Years of Acclinate's Innovation

Reliant Glycosciences, Supported by the Innovate Alabama Supplemental Grant, Host Events for Patients with IgA Nephropathy Birmingham, AL / December 2023 – In 2022, Reliant Glycosciences, LLC (Reliant) received an Innovate Alabama Supplemental Grant for $247,500. This grant is one of the first of its kind in the state of Alabama and provides support for additional work related to a Phase II Award of a Small Business Innovation Research (SBIR) grant from the National Institutes of Health.

Reliant focuses on developing diagnostics and prognostic tools for patients with IgA nephropathy (IgAN). IgAN is the most common form of glomerulonephritis in the world and affects more than 150,000 Americans. It is even more prevalent in other countries and regions (Europe, Japan, Singapore, and India). Glomerulonephritis is a form of kidney disease that injures the glomeruli, the filtering units of the kidneys. Several of the Reliant Founders helped to define IgAN as an autoimmune disease: Immune complexes are formed from immunoglobulin A protein lacking some sugars (galactose-deficient IgA) bound by immunoglobulin G antibodies (IgG). These complexes form in the blood and ultimately accumulate in the kidneys causing injury.

With the help of the Innovate Alabama Supplemental Grant, Reliant has hosted several events for IgAN patients. Each event has enabled Reliant to raise awareness of their assays. Ultimately, Reliant’s assays will improve diagnosis and treatment for IgAN. To organize these events, Reliant partnered with the IgA Nephropathy Foundation. This non-profit organization seeks to improve the lives of patients with IgAN through commitments to research, public education, and patient service. The most recent event in July, called SPARK, allowed Reliant to connect with over 250 patients, caregivers, and family members.

Reliant has developed two assays for IgAN-specific biomarkers. In June, Reliant announced the launch of “The GalD Assay” for release by the end of 2023 as a research tool for the measurement of blood levels of galactose-deficient IgA1. The second assay measures blood levels of the IgG antibody that binds to galactose-deficient IgA1; it is scheduled for release in 2024.

With the help of the regional events for IgAN patients, the SBIR Phases I and II, consultations with key opinion leaders in the field, the IgA Nephropathy Foundation, and the Innovate Alabama Supplement Grant Program, Reliant has established their footprint in the Birmingham biotech sector.

Dr. Matthew Renfrow, Reliant Co-Founder, states, “We are proud to be a true homegrown startup that is having an impact worldwide for patients with IgA nephropathy.”

To learn more about Innovate Alabama, visit the website at: Innovate Alabama – Helping Innovators Grow Roots

To learn more about Reliant Glycosciences, visit the website at: Biomarker | Reliant Glycosciences, LLC

To learn more about the IgA Nephropathy Foundation, visit the website at: IgA Nephropathy Foundation

Written by: Tatum Street, MBA

Innovate Alabama awards $9.3 million to the inaugural designees of the Innovate Alabama Network

BIRMINGHAM, AL (October 26, 2023) – Innovate Alabama has announced the inaugural designees of the Innovate Alabama Network, a comprehensive resource to connect communities, nonprofits and higher education institutions across Alabama fostering innovation in their local footprint. Fifty-one designees in 17 Alabama counties make up the group, receiving $9.3 million in supporting funds from Innovate Alabama.

“The Innovate Alabama Network is a major step forward to growing the entrepreneurial and innovation ecosystem in Alabama,” said Innovate Alabama CEO Cynthia Crutchfield. “By providing funding and resources to our local communities, nonprofits and higher education institutions, we are developing a statewide network for innovation programming and catalyzing entrepreneurship in all of our communities, both rural and urban.”

By investing in these organizations who are shaping the state’s entrepreneurial ecosystem, Innovate Alabama is driving innovation-related activities, encouraging collaboration across the state and providing vital seed funding to propel innovation forward at the community and regional level. In total, 30 nonprofit entities, 11 communities and municipalities and 10 colleges and universities received an Innovate Alabama Network Designation.

“I’m encouraged and energized to see the overwhelming response to the Innovate Alabama Network,” said Innovate Alabama Board Chairman and Alabama State Director of Finance Bill Poole. “We have a diverse ecosystem for innovation in Alabama, so to bring all of these partners together in one place to partner and collaborate together on moving our state forward is a move in the right direction for Alabama.”

Applications for the second round of the Innovate Alabama Network are now open. Any interested Alabama community, nonprofit or higher education institution can apply by 5 p.m. CT on Friday, January 5, 2024. Innovate Alabama will host a series of informational webinars and office hours through the end of the year for organizations that want to learn more about the program. To register for these sessions, visit this link.

Program guidelines have evolved since the Innovate Alabama Network was initially launched. For important key program updates and to apply to the second round of the Innovate Alabama Network, visit innovatealabama.org/innovate-alabama-network.

Designees from the first round of the Innovate Alabama Network include the following communities, nonprofits and higher education institutions:

Communities:

• City of Auburn
• City of Bessemer
• City of Dothan
• City of Henagar
• City of Hoover
• City of Marion
• City of Mobile
• City of Pinson
• City of Talladega
• Shelby County
• Town of Pike Road

Nonprofit entities:

• Alabama Artificial Intelligence Center of Excellence
• Alabama Trails Foundation
• Baldwin County Community and Economic Development Foundation
• BioAlabama
• Birmingham Bound
• Birmingham Business Alliance
• Bronze Valley Foundation
• Cordova Economic Industrial Development Authority
• Ed Farm
• Economic Development Partnership of Alabama
• Hardware Park
• HBCU Cares
• Higher Education Partnership
• Innovation Depot
• Innovation Portal
• Main Street Marion
• McWane Science Center
• Montgomery Tech Lab
• Prosper Foundation
• QIE Foundation
• REV Birmingham
• Singing River Trail
• Southern Research
• Teach2Lead
• The Alabama Collective
• The Arc of Madison County
• The E-Center
• The Overton Project
• United Way of Southwest Alabama
• Venture for America

Higher Education Institutions:

• Alabama A&M University
• Alabama State University
• Auburn Lowder Center for Family and Entrepreneurship
• Drake State Community and Technical College
• Talladega College
• Trenholm State University
• Troy University
• University of Alabama
• University of Alabama at Birmingham
• University of South Alabama

###

About Innovate Alabama

Innovate Alabama is Alabama’s first statewide public-private partnership focused on entrepreneurship, technology and innovation with a mission to help innovators grow roots here in Alabama. Innovate Alabama was established to implement the initiatives and recommendations set forth in the Alabama Innovation Commission’s report, including smart policy solutions that will create a more resilient, inclusive and robust economy to remain competitive in a 21st-century world. With founding CEO Cynthia Crutchfield leading the charge, Innovate Alabama is also made up of a board of 11 innovation leaders appointed by Gov. Ivey, collaborating across sectors to advance industries, drive technology and facilitate an environment where innovation and entrepreneurship thrive. Learn more about Innovate Alabama at www.innovatealabama.org.

November 10, 2022 - TIME revealed its annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives.

We are honored to have GRAIL’s Galleri® test named among the top inventions of 2022. The Galleri test is a multi-cancer early detection (MCED) test that can detect a shared cancer signal across more than 50 types of cancer1 through a simple blood draw.

Using next-generation genomic sequencing and machine-learning technologies, the Galleri test detects a signal associated with cancer and includes one or two predictions of where in the body the cancer signal originated.

“I am thrilled to see the Galleri test included in TIME’s list of best inventions of 2022,” said Bob Ragusa, chief executive officer at GRAIL. “We believe strongly in the importance of early cancer detection and the impact it can make on patients’ lives. This test is a promising new tool in our fight against cancer.”

To compile the list, TIME solicited nominations from TIME’s editors and correspondents around the world, and through an online application process, paying special attention to growing fields—such as the electric vehicle industry, medical care, and the metaverse. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.

Of the new list, TIME’s editors write: “The result is a list of 200 groundbreaking inventions (and 50 special mention inventions)—including life-mapping artificial intelligence, diamonds made from excess carbon in the air, and the most powerful telescope ever—that are changing how we live, work, play, and think about what’s possible.”

See full list HERE.

Dr. Milton Harris, Serina Therapeutics Board Chairman and HudsonAlpha Board Member, was awarded the Per-Åke Albertsson Award for his life-long work in Bio-partitioning and Purification of Aqueous Polymer two-phase systems. Dr. Harris will receive the award at BPP 2022 in Aveiro, Portugal at the end of September. 

Dr. Per-Åke Albertsson was a Swedish Biochemist, Educator and a Member of the Royal Swedish Academy of Sciences. In his memory, this award is given to exemplary scientists who have contributed in the field of separation sciences.  

Dr. Milton Harris founded Shearwater Polymers, Inc. in 1992 to advance polyethylene glycol “PEG” technology.  The company later became Nektar Therapeutics. Dr. Harris co-founded Serina Therapeutics in 2006 and joined the Board of the HudsonAlpha Institute for Biotechnology at the same time. Dr. Harris is also the recipient of the Nagai Innovation Award (2005, Controlled Release Society) and a member of the Swedish Academy of Engineering Sciences.

BIO Alabama CEO Headed to Oklahoma

September 14, 2022

BIO Alabama CEO Rachel Lane, PhD, RD steps down from the association at the end of September to transition her efforts to the Tulsa Innovation Labs Canopy Virtual HealthTech program in Tulsa, Oklahoma.

Under Dr. Lane’s leadership, BIO Alabama and the state’s bioscience industry grew significantly, marked by the following key accomplishments:

• Annual Conference | This in-person, two-day meeting gathered over 200 statewide industry partners and featured leaders and speakers from across the US.
• Inaugural RALLY | This reverse-pitch event was supported by the AL Department of Commerce and connected local and national industry companies with Alabama academic institutions for collaboration.
• Workforce Development | This initiative in collaboration with the AL Department of Commerce and AIDT charts a path for upscaling Alabama’s bioscience workforce.
• Small Business Innovation Research (SBIR)/Small Business Tech Transfer Research (STTR) Award Workshops | The workshops are sponsored by the Innovation Corporation and connect innovators with federal agencies and information about nondilutive funding.
• Platforms | BIO Alabama’s advocacy on behalf of Alabama bioscience companies create opportunities for innovators to be showcased on regional, national, and international stages.

BIO Alabama held their first in-person conference in six years in April 2022.

“Dr. Lane applied her vision and knowledge to take our industry to new, innovative levels,” said Chairperson Kacee Sims, PhD, director of marketing and technical services at Avanti Polar Lipids, Inc. “Losing her leadership is a disappointment, but I know she will continue to be an ambassador for us beyond our state’s lines.”

Dr. Lane expressed gratitude to the Alabama bioscience and innovation community, stating “We have made significant strides toward our vision for the industry, thanks to the collaborative, welcoming spirit of this community. There is still work to be done, and it must be done together. The Alabama spirit that fueled our progress these past two years will continue to propel momentum forward.”

Dr. Lane presents at the EDAA 2022 winter conference with panelists Vince Perez (AL Department of Commerce), Amy Sturdivant (58, Inc), and Blair King (Alabama Power).

The BIO Alabama executive committee is strategizing a transition plan to ensure the continuation of Alabama’s forward progress in the industry.

“BIO AL is a critical catalyst for our state’s industry,” stated Bill Dean, executive director of the Auburn Research and Technology Foundation and member of BIO AL’s executive committee. “We are evaluating Dr. Lane’s thoughtful transition plan and are committed to continuing the momentum we have gained over the last two years.”

BIO Alabama was founded in 1998 by industry leaders from across the state and is the state affiliate for BIO International. Bioscience companies in Alabama feed, fuel, and heal the world. BIO Alabama is committed to developing and fortifying the ecosystem that promotes the success of these companies by ensuring these companies have the intellectual property, people, space, capital, and business environment to complete their mission.

Learn more about BIO Alabama at bioalabama.com.